has part
is_specified_input_of
is_manufactured_by
has role
immunizes host
Homo sapiens
ActHIB
103935
Preparation: The vaccine consists of the Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high molecular weight polymer prepared from the Haemophilus influenzae type b (HiB) strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid. The tetanus toxoid is prepared by extraction, ammonium sulfate purification, and formalin inactivation of the toxin from cultures of Clostridium tetani (Harvard strain) grown in a modified Mueller and Miller medium. The toxoid is filter sterilized prior to the conjugation process. When ActHIB vaccine is reconstituted with saline diluent, each single dose of 0.5 mL is formulated to contain 10 mu g of purified capsular polysaccharide conjugated to 24 mu g of inactivated tetanus toxoid, and 8.5% of sucrose (ActHIB 2005).
Reference: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=157&keywords=
PMID: 1735812
CVX: 48
Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)
Kallan Roan, Oliver He
PMID:
PMID: 1517908
ActHIB
ActHIB vaccine is indicated for the active immunization of infants and children 2 months through 5 years of age for the prevention of invasive disease caused by H influenzae type b.
https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm174743.htm
vaccine
https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM109841.pdf
Haemophilus influenzae serotype b vaccine
USA licensed vaccine role
Canada licensed vaccine role
intramuscular vaccination
capsular polysaccharide of pathogen organism as vaccine component
USA licensed vaccine
vaccine conjugate protein
Sanofi Pasteur, SA